Evidence map›Paper›PMID 32183032›Full record

ArticleMolecules (Basel, Switzerland)2020

Design and Characterizations of Inhalable Poly(lactic-

Hideyuki Sato, Aiko Tabata, Tatsuru Moritani, Tadahiko Morinaga, Takahiro Mizumoto, Yoshiki Seto, Satomi Onoue

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Biopolymeric Inhalable Dry Powders for Pulmonary Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Hideyuki SatoLaboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.ORCID 0000-0002-5155-2003
Aiko TabataLaboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
Tatsuru MoritaniFunctional Material Development Center, Imaging Engine Development Division, RICOH Company, Ltd., 16-1 Honda-machi, Numazu-shi, Shizuoka 410-1458, Japan.
Tadahiko MorinagaFunctional Material Development Center, Imaging Engine Development Division, RICOH Company, Ltd., 16-1 Honda-machi, Numazu-shi, Shizuoka 410-1458, Japan.
Takahiro MizumotoILS Inc., 1-2-1 Kubogaoka, Moriya, Ibaraki 302-0104, Japan.
Yoshiki SetoLaboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
Satomi OnoueLaboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.

Funding

Japan Society for the Promotion of Science 17K08453Japan Society for the Promotion of Science 17K15516Japan Society for the Promotion of Science 18K14885
6 · The paper itself

Abstract

The present study aimed to develop inhalable poly (lactic-

Indexed as

MicrospheresAdministration, InhalationAnimalsCalcitoninDelayed-Action PreparationsDesiccationMaleParticle SizePolylactic Acid-Polyglycolic Acid CopolymerPowdersProtein Structure, SecondaryRats, Sprague-DawleyCalcitoninDelayed-Action PreparationsPolylactic Acid-Polyglycolic Acid CopolymerPowderssalmon calcitonindry powder inhalerfine droplet drying processpoly(lactic-co-glycolic acid)salmon calcitoninsustained release

Identifiers

PMID32183032
PMCPMC7144118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.